Elevated Soluble CD163 Plasma Levels Are Associated with Disease Severity in Patients with Hemorrhagic Fever with Renal Syndrome

被引:10
|
作者
Wang, Junning [1 ]
Guo, Weijuan [2 ]
Du, Hong [1 ]
Yu, Haitao [1 ]
Jiang, Wei [1 ]
Zhu, Ting [1 ]
Bai, Xuefan [1 ]
Wang, Pingzhong [1 ]
机构
[1] Fourth Mil Med Univ, Tangdu Hosp, Dept Infect Dis, Xian 710032, Shaanxi Provinc, Peoples R China
[2] Chang An Hosp, Dept Obstet & Gynecol, Xian, Shaanxi Provinc, Peoples R China
来源
PLOS ONE | 2014年 / 9卷 / 11期
基金
中国国家自然科学基金;
关键词
HEMOGLOBIN SCAVENGER RECEPTOR; MONOCYTE SUBSET; EXPRESSION; PATHOGENESIS; MACROPHAGES; ACTIVATION; INFECTION; MARKER;
D O I
10.1371/journal.pone.0112127
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Hantaan virus is a major zoonotic pathogen that causesing hemorrhagic fever with renal syndrome (HFRS). Although HFRS pathogenesis has not been entirely elucidated, the importance of host-related immune responses in HFRS pathogenesis has been widely recognized. CD163, a monocyte and macrophage-specific scavenger receptor that plays a vital function in the hosts can reduce inflammation, is shed during activation as soluble CD163 (sCD163). The aim of this study was to investigate the pathological significance of sCD163 in patients with HFRS. Methods: Blood samples were collected from 81 hospitalized patients in Tangdu Hospital from October 2011 to January 2014 and from 15 healthy controls. The sCD163 plasma levels were measured using a sandwich ELISA, and the relationship between sCD163 and disease severity was analyzed. Furthermore, CD163 expression in 3 monocytes subset was analyzed by flow cytometry. Results: The results demonstrated that sCD163 plasma levels during the HFRS acute phase were significantly higher in patients than during the convalescent stage and the levels in the healthy controls (P<0.0001). The sCD163 plasma levels in the severe/critical group were higher than those in the mild/moderate group during the acute (P<0.0001). A Spearman correlation analysis indicated that the sCD163 levels were positively correlated with white blood cell, serum creatine, blood urea nitrogen levels, while they were negatively correlated with blood platelet levels in the HFRS patients. The monocyte subsets were significantly altered during the acute stage. Though the CD163 expression levels within the monocyte subsets were increased during the acute stage, the highest CD163 expression level was observed in the CD14++CD16+ monocytes when compared with the other monocyte subsets. Conclusion: sCD163 may be correlated with disease severity and the disease progression in HFRS patients; however, the underlying mechanisms should be explored further.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] THE MACROPHAGE ACTIVATION MARKER SOLUBLE CD163 IS ELEVATED AND ASSOCIATED WITH LIVER DISEASE PHENOTYPE IN PATIENTS WITH WILSON'S DISEASE
    Glavind, Emilie
    Gotthardt, Daniel Nils
    Pfeiffenberger, Jan
    Sandahl, Thomas Damgaard
    Bashlekova, Teodora
    Willemoe, Gro
    Hasselby, Jane
    Weiss, Karl Heinz
    Moller, Holger
    Vilstrup, Hendrik Von Arenstorff
    Lee, William M.
    Schilsky, Michael L.
    Ott, Peter
    Gronbaek, Henning
    HEPATOLOGY, 2019, 70 : 1170A - 1171A
  • [22] The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson’s disease
    Emilie Glavind
    Daniel N. Gotthardt
    Jan Pfeiffenberger
    Thomas Damgaard Sandahl
    Teodora Bashlekova
    Gro Linno Willemoe
    Jane Preuss Hasselby
    Karl Heinz Weiss
    Holger Jon Møller
    Hendrik Vilstrup
    William M. Lee
    Michael L. Schilsky
    Peter Ott
    Henning Grønbæk
    Orphanet Journal of Rare Diseases, 15
  • [23] The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease
    Glavind, Emilie
    Gotthardt, Daniel N.
    Pfeiffenberger, Jan
    Sandahl, Thomas Damgaard
    Bashlekova, Teodora
    Willemoe, Gro Linno
    Hasselby, Jane Preuss
    Weiss, Karl Heinz
    Moller, Holger Jon
    Vilstrup, Hendrik
    Lee, William M.
    Schilsky, Michael L.
    Ott, Peter
    Gronbaek, Henning
    ORPHANET JOURNAL OF RARE DISEASES, 2020, 15 (01)
  • [24] Soluble (s)CD163 a macrophage activation marker is associated with liver disease severity in patients with Wilson's disease
    Groenbaek, H.
    Gotthardt, D. N.
    Bjoerklund, J.
    Pfeiffenberger, J.
    Moller, H. J.
    Bashlekova, T.
    Ott, P.
    Weiss, K. -H.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S175 - S175
  • [25] Increased serum levels of soluble CD163 in patients with scleroderma
    Shimizu, K.
    Ogawa, F.
    Takenaka, M.
    Sato, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 : S22 - S22
  • [26] ELEVATED SOLUBLE CD163 LEVELS ARE ASSOCIATED WITH THROMBOCYTOPENIA-ASSOCIATED MULTIPLE ORGAN FAILURE (TAMOF) IN PEDIATRIC SEPSIS PATIENTS
    Halstead, E.
    Hall, Mark
    Aneja, Raj
    Jones, Jennifer
    Carcillo, Joseph
    CRITICAL CARE MEDICINE, 2010, 38 (12) : U116 - U116
  • [27] Serum levels of soluble CD163 in patients with systemic sclerosis
    Nakayama, Wakana
    Jinnin, Masatoshi
    Makino, Katsunari
    Kajihara, Ikko
    Makino, Takamitsu
    Fukushima, Satoshi
    Inoue, Yuji
    Ihn, Hironobu
    RHEUMATOLOGY INTERNATIONAL, 2012, 32 (02) : 403 - 407
  • [28] Serum levels of soluble CD163 in patients with systemic sclerosis
    Wakana Nakayama
    Masatoshi Jinnin
    Katsunari Makino
    Ikko Kajihara
    Takamitsu Makino
    Satoshi Fukushima
    Yuji Inoue
    Hironobu Ihn
    Rheumatology International, 2012, 32 : 403 - 407
  • [29] Increased serum levels of soluble CD163 in patients with scleroderma
    Shimizu, Kazuhiro
    Ogawa, Fumihide
    Yoshizaki, Ayumi
    Akiyama, Yuichiro
    Kuwatsuka, Yutaka
    Okazaki, Shihoko
    Tomita, Hajime
    Takenaka, Motoi
    Sato, Shinichi
    CLINICAL RHEUMATOLOGY, 2012, 31 (07) : 1059 - 1064
  • [30] Increased serum levels of soluble CD163 in patients with scleroderma
    Kazuhiro Shimizu
    Fumihide Ogawa
    Ayumi Yoshizaki
    Yuichiro Akiyama
    Yutaka Kuwatsuka
    Shihoko Okazaki
    Hajime Tomita
    Motoi Takenaka
    Shinichi Sato
    Clinical Rheumatology, 2012, 31 : 1059 - 1064